Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glyhexamide SCHEMBL27491055 | 1.00 | ADORA3 (0.64) | ADORA3ALDH1A1TDP1LMNATHRB | |
| SCHEMBL11763585 | 0.86 | ADORA3 (0.54) | ADORA3ALDH1A1TDP1LMNATHRB | |
| SCHEMBL11765186 | 0.86 | ADORA3 (0.54) | ADORA3ALDH1A1TDP1LMNATHRB | |
| SCHEMBL11764729 | 0.84 | ADORA3 (0.55) | ADORA3ALDH1A1TDP1LMNATHRB | |
| SCHEMBL11761600 | 0.83 | ADORA3 (0.54) | ADORA3ALDH1A1TDP1LMNATHRB | |
| SCHEMBL11760402 | 0.83 | ADORA3 (0.54) | ADORA3ALDH1A1TDP1LMNATHRB | |
| SCHEMBL11766631 | 0.83 | ADORA3 (0.54) | ADORA3ALDH1A1TDP1LMNATHRB | |
| SCHEMBL11761408 | 0.83 | ADORA3 (0.50) | ADORA3ALDH1A1TDP1LMNATHRB | |
| SCHEMBL11766694 | 0.82 | ADORA3 (0.52) | ADORA3ALDH1A1TDP1LMNATHRB | |
| SCHEMBL11764027 | 0.82 | ADORA3 (0.52) | ADORA3ALDH1A1TDP1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2809 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12208071-B2 | Glucagon receptor antagonists | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2025-01-28 | — | — | US | claimed |
| US-12186329-B2 | Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-01-07 | — | — | US | claimed |
| US-20240316048-A1 | Prevention of Pancreatic Cell Degeneration | MELIOR PHARMACEUTICALS I, INC. | 2024-09-26 | — | — | US | claimed |
| US-12070461-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2024-08-27 | — | — | US | claimed |
| US-20230263821-A1 | Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-08-24 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20210361652-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | MELIOR PHARMACEUTICALS I, INC. | 2021-11-25 | — | — | US | claimed |
| US-20210315908-A1 | COMPOSITIONS AND METHODS RELATED TO CHOLIC ACID 7-SULFATE AS A TREATMENT FOR DIABETES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-10-14 | — | — | US | claimed |
| CN-113423404-A | Xanthine derivative pharmaceutical composition and preparation method thereof | 成都苑东生物制药股份有限公司 | 2021-09-21 | — | — | CN | claimed |
| EP-1931350-B2 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-04 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6150383-A | COMPRISING AN INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH ONE OR MORE OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN MECHANISM OF ACTION; LIPID/GLYCOMETABOLISM DISORDERS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-11-21 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000027401-A1 | COMBINATIONS FOR DIABETES WHICH CONTAIN A SULFONYLUREA, A GLITAZONE AND A BIGUANIDE | WARNER-LAMBERT COMPANY (US) | 2000-05-18 | — | — | WO | claimed |
| CN-1244801-A | Sulfonylurea-glitazone synergistic combinations for diabetes | WARNER LAMBERT CO (US) | 2000-02-16 | — | — | CN | claimed |
| US-6011049-A | Combinations for diabetes | WARNER-LAMBERT COMPANY (US) | 2000-01-04 | — | — | US | claimed |
| EP-0957923-A1 | SULFONYLUREA-GLITAZONE SYNERGISTIC COMBINATIONS FOR DIABETES | WARNER-LAMBERT COMPANY (US) | 1999-11-24 | — | — | EP | claimed |
| US-5972973-A | SYNERGISTIC MIXTURE; GLUCOSE CONTROL | WARNER-LAMBERT COMPANY (US) | 1999-10-26 | — | — | US | claimed |
| US-5859037-A | MIXTURE SYNERGISTIC FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS IN HUMANS, WHICH ALSO IMPROVES GLYCEMIC CONTROL | WARNER-LAMBERT COMPANY (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998036755-A1 | SULFONYLUREA-GLITAZONE SYNERGISTIC COMBINATIONS FOR DIABETES | WARNER LAMBERT COMPANY (US) | 1998-08-27 | — | — | WO | claimed |